Medicare Enrolled
Dr. Ahmad Aslam, MD
Cardiovascular Disease · Tomball, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Aslam from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Aslam? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Aslam
Dr. Ahmad Aslam is a cardiovascular disease in Tomball, TX, with 20 years in practice. Based on federal Medicare data, Dr. Aslam performed 19,104 Medicare services across 6,694 unique beneficiaries.
Between the years covered by Open Payments, Dr. Aslam received a total of $6,682 from 32 pharmaceutical and/or device companies across 195 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Aslam is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 1% volume in TX$ $6,682 industry payments
Medicare Practice Summary
Medicare Utilization ↗19,104
Medicare services
Top 1% in TX for cardiovascular disease
6,694
Unique beneficiaries
$101
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~955 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 3,013 | $32 | $168 |
| Office visit, established patient (30-39 min) | 2,304 | $95 | $533 |
| Remote patient monitoring management, 20 min/month | 1,658 | $39 | $206 |
| Chronic care management, additional 20 min/month | 1,638 | $38 | $199 |
| Electrocardiogram (EKG), 12-lead | 1,424 | $11 | $60 |
| Chronic care management, first 20 min/month | 1,411 | $50 | $263 |
| Remote patient monitoring device, 30 days | 1,331 | $40 | $230 |
| Regadenoson injection (Lexiscan) for heart stress test | 1,168 | $43 | $221 |
| Office visit, established patient (20-29 min) | 544 | $66 | $378 |
| Echocardiogram, transthoracic | 450 | $150 | $843 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 360 | $57 | $298 |
| Injection, aminophyllin, up to 250 mg | 347 | $7 | $47 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 319 | $355 | $454 |
| Nuclear medicine study of heart muscle blood flow by pet | 308 | $148 | $746 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 285 | $1,970 | $9,877 |
| Injection, dipyridamole, per 10 mg | 280 | $3 | $14 |
| Hospital follow-up visit, moderate complexity | 254 | $65 | $293 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 240 | $147 | $805 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 182 | $96 | $511 |
| Prothrombin time test (blood clotting) | 175 | $4 | $18 |
| New patient office visit, complex (60-74 min) | 150 | $162 | $919 |
| Complex chronic care management services for two or more chronic conditions, each additional 60 minutes of clinical staff time directed by health care professional, per calendar month | 124 | $56 | $290 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 118 | $21 | $107 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 118 | $682 | $3,752 |
| Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | 104 | $107 | $552 |
| Office visit, established patient (10-19 min) | 97 | $45 | $236 |
| Injection of chemical agent into single incompetent vein of leg using ultrasound guidance | 88 | $1,087 | $5,791 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 83 | $15 | $79 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 64 | $894 | $4,737 |
| Ultrasound of both sides of head and neck blood flow | 61 | $153 | $820 |
| Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 59 | $200 | $1,050 |
| Programming of dual lead pacemaker system | 53 | $24 | $158 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 50 | $10 | $52 |
| Ultrasound of leg arteries or artery grafts | 42 | $194 | $1,037 |
| Initial hospital admission, high complexity | 39 | $141 | $813 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 35 | $359 | $1,910 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 34 | $70 | $92 |
| Cardiac catheterization | 33 | $225 | $1,211 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 23 | $1,071 | $5,427 |
| Ultrasound of heart, follow-up | 14 | $81 | $419 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 13 | $50 | $318 |
| Coronary stent placement | 11 | $483 | $2,421 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
2.9% high complexity
18.3% medium
78.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,682
Total received (2018-2024)
Avg $955/year across 7 years
Top 41% in TX for cardiovascular disease
32
Companies
195
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,682 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$889
2023$1,109
2022$936
2021$837
2020$1,298
2019$1,305
2018$308
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Abbott Laboratories
$4,056
Philips North America LLC
$524
Amgen Inc.
$452
Merck Sharp & Dohme LLC
$211
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$174
Novartis Pharmaceuticals Corporation
$145
PFIZER INC.
$121
Janssen Pharmaceuticals, Inc
$111
AstraZeneca Pharmaceuticals LP
$100
BIOTRONIK INC.
$78
Actelion Pharmaceuticals US, Inc.
$75
Allergan Inc.
$72
Boston Scientific Corporation
$66
Gilead Sciences, Inc.
$51
Bolton Medical Inc
$46
Boehringer Ingelheim Pharmaceuticals, Inc.
$41
E.R. Squibb & Sons, L.L.C.
$37
BARD PERIPHERAL VASCULAR, INC.
$36
Impulse Dynamics (USA) Inc.
$35
Kestra Medical Technology Services, Inc.
$31
Novo Nordisk Inc
$29
Edwards Lifesciences Corporation
$28
Esperion Therapeutics, Inc.
$23
Amarin Pharma Inc.
$21
AngioDynamics, Inc.
$17
SANOFI-AVENTIS U.S. LLC
$16
iRhythm Technologies, Inc.
$16
BOSTON SCIENTIFIC CORPORATION
$15
Tactile Systems Technology Inc
$14
Resmed Corp
$13
Venclose Inc.
$13
Merck Sharp & Dohme Corporation
$13
Top 3 companies account for 75.3% of total payments
Associated products mentioned in payments ›
(5023) DS Zenition 70 · (5153) Azurion 5 M20 GC · ASSURITY · AVEIR · AirMini · Assure WCD · Assurity Pacemaker · BIOMONITOR · BRILINTA · BYDUREON · CONFIRM RX · Confirm Rx · Connectivity and Remote care · Corlanor · EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) · ELIQUIS · ENSITE PRECISION · ENTRESTO · EVRSF · Ensite Cardiac Mapping System · FARXIGA · FLEXITOUCH · HeartMate 3 Left Ventricular Dev · JARDIANCE · LEQVIO · LINZESS · LifeVest · MERLIN@HOME · MRI Ready Leads · MULTAQ · Merlin Connectivity and Remote · NEXLETOL · OPSUMIT · OPTIMIZER · Ozempic · QUARTET · Quadra Allure MP RF CRT Pacemkr · Quartet CRT Lead · Relay Grafts · Repatha · VENOVO · VERQUVO · VIBERZI · VYNDAMAX · Vascepa · VenaCure 1470 Pro · WATCHMAN · WATCHMAN Access System · XARELTO · XIENCE SKYPOINT · ZIO Patch
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $35 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
170
Per 100K population
3.6
County median income
$73,104
Nearest hospital
HCA HOUSTON HEALTHCARE TOMBALL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Aslam is a clinical cardiology specialist, with above-average Medicare volume (top 1% in TX), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Aslam experienced with management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes?
Based on Medicare claims data, Dr. Aslam performed 3,013 management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Aslam receive payments from pharmaceutical companies?
Yes. Dr. Aslam received a total of $6,682 from 32 companies across 195 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Aslam's costs compare to other cardiovascular diseases in Tomball?
Dr. Aslam's average Medicare payment per service is $101. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Aslam) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in Tomball
Browse cardiovascular diseases in Tomball ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in TX
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in TX
Which TX cardiovascular diseases receive the most from drug and device companies.
By company
Abbott Laboratories Payments to Doctors
See all physicians who received payments from Abbott Laboratories.
By company
Philips North America LLC Payments to Doctors
See all physicians who received payments from Philips North America LLC.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology